JPRN-jRCT2031210234进行中（未招募）2 期
[M19-051] Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Yamazaki Hayato0 个研究点目标入组 160 人开始时间: 2021年8月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 65age old（—）
- 性别
- All
入选标准
- •Clinical diagnosis of non-segmental vitiligo (NSV) and no segmental or localized vitiligo.
- •Participants with all of the following at Screening and Baseline.
- •- Visits: >= 0.5 Facial Vitiligo Area Scoring Index (F-VASI) and >= 5 total vitiligo area scoring index (T-VASI).
- •- Participants who have had prior exposure to immunomodulatory biologic therapy, for any indications, but discontinued the biologic therapy prior to the first dose of study drug. Recommended washout periods for biologic therapies include >= 4 weeks for etanercept; >= 8 weeks for adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and ixekizumab; >= 16 weeks for secukinumab; and >= 12 weeks for ustekinumab. For biologic therapies not specified, therapies must be discontinued at least 5 times the mean terminal elimination half-life of a drug or 3 months prior to Baseline, whichever is longer.
排除标准
- •Participants with segmental or localized vitiligo.
- •Participants with other skin conditions that would interfere with evaluation of vitiligo, participants with uncontrolled thyroid disease, and participants with > 33% leukotrichia on the face or > 33% leukotrichia on the body (including face).
- •Participants previously treated with any topical or systemic janus kinase (JAK) inhibitor or permanent skin bleaching agents.
- •Participants treated with any systemic vitiligo therapy (e.g., methotrexate, mycophenolate mofetil, corticosteroids), supplemental vitiligo therapy (antioxidants/vitamins/herbal medicine/traditional Chinese medicine), and/or topical vitiligo therapy including permanent or temporary tattoos within a minimum of 30 days prior to the first dose of study drug (Note: Camouflage and makeup may be used).
- •Participants treated with any phototherapy, including excimer (or other forms of laser therapy), within a minimum of 12 weeks prior to the first dose of study drug.
- •Participants have history of malignancy other than successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.
- •Recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting, and aorto-coronary bypass surgery;
- •History of an organ transplant which requires continued immunosuppression;
- •History of gastrointestinal (GI) perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment;
- •Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery; subjects with a history of gastric banding/segmentation are not excluded;
- •Uncontrolled thyroid disease;
研究者
相似试验
已完成
不适用
A retrospective study to evaluate complications and long term outcomes of endoscopic nasopancreatobiliary drainagePancreatobiliary diseasesJPRN-UMIN000010245Department of Gastroenterology and Hepatology, Hokkaido University Hospital1,000
招募中
不适用
The evaluation of adverse events and theraputic effects using divided CDDP for advanced urothelial carcinoma patients with Chronic Kidney Disease.rothelial CarcinomaJPRN-UMIN000009202agoya Univerity, Depatment of Urology20
招募中
不适用
Prospective evaluation of adverse events during neonatal endotracheal intubationsRespiratory insufficiency in preterm and term babiesDRKS00013575Zentrum für Kinder- und Jugendmedizin Universitätsmedizin Mainz, Abteilung Neonatologie93
尚未招募
Unknown
Adverse Events during Intrahospital Transport of CriticallyIll PatientsCTRI/2024/07/070693Indira Gandhi Government Medical College
招募中
不适用
The evaluation of the adverse effects in the prostate cancer patient who received a focal brachytherapy.Prostate canerJPRN-UMIN000026453Tokyo Metropolitan Police Hospital20